tiprankstipranks
Assertio Therapeutics Reports Strong Q3 and Board Changes
Company Announcements

Assertio Therapeutics Reports Strong Q3 and Board Changes

Don't Miss our Black Friday Offers:

The latest update is out from Assertio Therapeutics ( (ASRT) ).

In an eventful third quarter, Assertio Holdings reported net product sales of $28.7 million, with Rolvedon delivering stable sales amid pricing pressures. The company saw a gross margin increase to 74% and a reduction in SG&A expenses, while cash reserves remained steady at $88.6 million. Significant board changes included the retirement of Peter Staple and Jeffrey Vacirca, with David Stark joining as a new independent director, bringing extensive legal and acquisition experience from Teva Pharmaceuticals.

See more data about ASRT stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyAssertio Holdings price target lowered to $2.15 from $2.75 at Alliance Global
TipRanks Auto-Generated NewsdeskAssertio Therapeutics’ Q3 2024 Earnings Overview
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App